Compare ACDC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACDC | AUPH |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 2.0B |
| IPO Year | 2021 | 2014 |
| Metric | ACDC | AUPH |
|---|---|---|
| Price | $6.84 | $15.98 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $5.50 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 1.4M | 1.3M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $1,941,800,000.00 | $283,055,000.00 |
| Revenue This Year | N/A | $17.54 |
| Revenue Next Year | $11.50 | $15.74 |
| P/E Ratio | ★ N/A | $66.00 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $3.08 | $7.29 |
| 52 Week High | $10.70 | $16.88 |
| Indicator | ACDC | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 54.94 |
| Support Level | $5.82 | $14.53 |
| Resistance Level | $7.85 | $16.29 |
| Average True Range (ATR) | 0.61 | 0.54 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 44.16 | 60.52 |
ProFrac Holding Corp is a technology-focused, vertically integrated energy services company providing hydraulic fracturing, proppant production, completion services, and related products, including distributed power generation, to upstream oil and natural gas companies in the United States. The Company operates through four segments: Stimulation Services, Proppant Production, Manufacturing, and Flotek. The Stimulation Services segment, which generates maximum revenue, provides hydraulic fracturing services using mobile units and auxiliary equipment. The Proppant Production segment supplies proppant, the Manufacturing segment sells engineered products such as pumps, valves, and piping, and Flotek is a chemistry and data technology company serving the E&P industry.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.